AOD-9604

Overview

AOD-9604 (an abbreviation of Anti-Obesity Drug 9604) is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH). Researchers at the Australian company Metabolic Pharmaceuticals took the fragment corresponding roughly to hGH residues 176-191, a stretch that earlier work had identified as the part of the hormone associated with fat metabolism, and made a small modification, producing the analog now known as AOD-9604. The central idea behind its development was that this fragment might retain growth hormone's fat-mobilizing ("lipolytic") activity while not triggering the other, broader effects of full-length growth hormone, such as raised IGF-1 or disturbed blood sugar.

That hypothesis drove a substantial drug-development program in the late 1990s and 2000s, including multiple human clinical trials in obesity. What those trials showed is the heart of the matter: in its pivotal human obesity studies, AOD-9604 did not produce statistically significant weight loss compared with placebo, and its development as an anti-obesity drug was discontinued around 2007. The compound was later explored for other uses and received a self-affirmed food-ingredient safety designation, but it has never been approved as a drug by any major regulator.

Chemistry and structure

AOD-9604 is a small peptide of 16 amino acids. Its sequence corresponds to the human growth hormone fragment hGH(177-191) with an additional tyrosine residue at the N-terminus (placed where the native sequence would otherwise begin), which is why it is often described as an analog of "hGH fragment 176-191." The molecule contains two cysteine residues that form a disulfide bond, giving it a small internal loop.

AOD-9604 should be distinguished from the unmodified peptide often sold as "hGH fragment 176-191." AOD-9604 is the tyrosine-modified analog developed and characterized by Metabolic Pharmaceuticals; the plain 176-191 fragment marketed elsewhere is closely related but not identical, and much of the formal research literature specifically concerns AOD-9604.

Mechanism of action

The proposed mechanism is the most-studied and most-cited aspect of AOD-9604, and it is drawn largely from rodent and cell-based experiments:

• Selective lipolysis without the full GH effect. Early metabolic studies reported that the hGH C-terminal fragment retained the lipolytic and anti-lipogenic (fat-mobilizing, fat-storage-reducing) activity of intact growth hormone, while AOD-9604 was specifically promoted as doing so without raising IGF-1 and without the adverse effects of GH on insulin sensitivity or blood glucose (Ng et al., 2000).
• Beta-3 adrenergic receptor involvement. In obese mice, chronic treatment with AOD-9604 increased fat oxidation and reduced body weight, and the fragment was reported to increase beta-3 adrenergic receptor (beta3-AR) expression in adipose tissue (Heffernan et al., 2001, Endocrinology). This is the basis for the frequently repeated marketing statement that AOD-9604 works "through beta-3 adrenergic signaling." The same knockout-mouse study found the fragment's reduction in body weight gain was not abolished in beta3-AR knockout mice, indicating its lipid-metabolic effects are not solely dependent on that receptor. The popular "beta-3 mechanism" framing is therefore an oversimplification.

Be precise about what this evidence supports. These mechanistic findings establish a plausible biological rationale in animals; they do not, by themselves, establish that AOD-9604 produces meaningful fat loss in people. As the clinical section below makes clear, the human efficacy data did not confirm the hoped-for weight-loss benefit.

Research and evidence

The evidence base divides into encouraging animal data, human obesity trials whose primary efficacy results were negative, and early preclinical exploration in osteoarthritis/cartilage.

Animal evidence: fat metabolism

In obese mice, chronic administration of AOD-9604 (or human GH) increased fat oxidation and produced weight loss, and the fragment was reported to alter beta-3 adrenergic receptor expression in adipose tissue, though its weight effect persisted in beta3-AR knockout mice (Heffernan et al., 2001). Earlier biochemical work characterized the fragment as a "lipolytic domain" of growth hormone that could increase lipolysis and reduce lipogenesis in adipose tissue (Ng et al., 2000). These are animal and laboratory findings.

Human obesity trials — the headline claim did not hold up

Metabolic Pharmaceuticals advanced AOD-9604 through a series of human clinical trials in obesity. Smaller and shorter studies reported modest numerical reductions in body weight relative to placebo, and the compound was consistently described as well tolerated, with no signal of effects on IGF-1, glucose, or insulin; a contemporaneous review summarized this early-stage profile (Wilding, 2004). However, the larger, longer pivotal trial did not demonstrate statistically significant weight loss versus placebo at its primary endpoint. Following that result, the company discontinued development of AOD-9604 as an anti-obesity drug around 2007.

This is the crux of an honest account of AOD-9604: despite an attractive hypothesis and a clean tolerability profile, the drug failed to prove meaningful efficacy for its intended purpose in humans. This stands in contrast to the later-developed and now-approved weight-loss medicines such as the GLP-1-based semaglutide and the multi-receptor agonist retatrutide, which have shown substantial, statistically significant weight loss in large randomized trials. Those are a different class of agents with a fundamentally different (and clinically demonstrated) evidence base.

Osteoarthritis and cartilage: early exploration

After obesity development ended, AOD-9604 was investigated for other uses, including cartilage repair and osteoarthritis. A study in a collagenase-induced rabbit knee osteoarthritis model reported that intra-articular AOD-9604, especially in combination with hyaluronic acid, was associated with cartilage regeneration (Kwon and Park, 2015). This is preliminary animal work; it does not establish efficacy or safety for joint disease in humans.

Safety and risks

Reported safety information comes from animal toxicology and from the human exposure accumulated during the obesity program:

• Across the development program and supporting toxicology, AOD-9604 was generally described as well tolerated, with adverse events reportedly comparable to placebo and no demonstrated genotoxicity in the assays performed (Moré and Kenley, 2014). The same reports emphasize the absence of effects on IGF-1, glucose, and insulin that distinguish it from full growth hormone.
• These data come from specific studies at specific doses; they do not amount to long-term safety surveillance in a broad population, and there is no large ongoing pharmacovigilance system for AOD-9604.
• Because AOD-9604 is widely sold as an unregulated research material, product identity, purity, and dose are not guaranteed. Investigators have documented seized "AOD9604" preparations that required laboratory characterization to even confirm their contents (Vanhee et al., 2014), illustrating that real-world products may not match their labels.

Regulatory status

AOD-9604 occupies an unusual position: it was a failed drug candidate that was later repurposed toward the food/supplement pathway, while remaining unapproved as a medicine.

• Drug approval. AOD-9604 is not an approved drug anywhere. Its obesity development was discontinued after the pivotal trials did not show significant efficacy. There is no FDA or EMA marketing authorization for any indication.
• GRAS (self-affirmed). The compound subsequently received a "Generally Recognized As Safe" (GRAS) determination for certain intended uses in foods, drinks, and dietary supplements (Moré and Kenley, 2014). This was a self-affirmed / conditional GRAS conclusion reached by an expert panel convened on behalf of the sponsor; it was not a finding that the substance is an effective weight-loss drug, and not a drug approval. GRAS speaks to a conclusion about safety for a defined food use, not to clinical efficacy, and self-affirmed GRAS is a sponsor-driven pathway distinct from formal FDA approval. The self-affirmed GRAS pathway itself is under active FDA reconsideration: in 2025 the FDA announced a notice of proposed rulemaking aimed at eliminating the ability of companies to self-affirm GRAS status without notifying the agency.
• Sport (WADA). AOD-9604 is prohibited in sport at all times (in- and out-of-competition). When WADA first addressed it (WADA Statement, 2013), the agency noted it was captured as a non-approved substance under category S0 because no government health authority had approved it for human use. On the current WADA Prohibited List it is named explicitly as a growth hormone fragment under category S2.2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), listed alongside hGH 176-191. Either way it is banned for athletes subject to the WADA Code, and anti-doping laboratories have developed methods to detect it (Cox et al., 2015; Schänzer and Thevis, 2017).

How it compares

In the weight-loss context specifically, AOD-9604 sits well below the approved incretin-based medicines on the strength of the evidence. The comparison is not close, and it is worth stating plainly:

The key distinction is evidentiary, not promotional. The incretin agonists semaglutide and tirzepatide have robust, replicated, statistically significant weight-loss results from large randomized controlled trials, which is why they are approved for obesity. AOD-9604's human obesity trials were negative at the primary endpoint, which is why its development was discontinued and it has never been approved. Tesamorelin is mechanistically unrelated (it stimulates the body's own growth-hormone axis) and is approved only for a narrow, specific indication rather than general weight loss. On current evidence, AOD-9604 does not belong in the same tier as the approved weight-loss medicines.

Common misconceptions

• "AOD-9604 is a proven fat-loss compound." Its pivotal human obesity trials did not show significant weight loss versus placebo, and drug development was discontinued. The positive fat-loss data are largely from mice.
• "It burns fat with no side effects, unlike growth hormone." The favorable tolerability profile (including no measured rise in IGF-1, glucose, or insulin) is genuine in the studies reported, but a clean safety profile is not the same as proven efficacy, and "no side effects" is an overstatement for any compound with limited long-term human data.
• "GRAS status means it's FDA-approved / clinically proven." It does not. GRAS is a food-ingredient safety pathway (here, self-affirmed), entirely separate from drug approval and unrelated to efficacy claims.
• "AOD-9604 and hGH fragment 176-191 are the same thing." They are closely related but not identical; AOD-9604 is the tyrosine-modified analog that was formally developed and studied.
• "It works just like the new weight-loss drugs." It does not. Approved agents such as semaglutide act through entirely different (GLP-1) mechanisms and have demonstrated large, statistically significant weight loss in trials — a clinical track record AOD-9604 never achieved. AOD-9604 is also unrelated in mechanism to growth-hormone-releasing peptides such as tesamorelin, an approved analog used for a different, specific indication.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" — checked against primary sources. A knowledgeable creator is not peer review, so every statement below was treated as a claim to verify, not a fact.

Verified additions

• The beta-3 mechanism is real but split, not exclusive. [Animal] In the beta3-adrenergic-receptor (beta3-AR) knockout study, chronic AOD-9604 treatment failed to reproduce the body-weight loss and increased lipolysis seen in wild-type mice — so those chronic effects genuinely require beta3-AR — yet AOD-9604's acute effects on energy expenditure and fat oxidation still occurred in the knockout animals, indicating additional beta3-independent actions (Heffernan et al., Endocrinology 2001).
• A 2024 peer-reviewed review situates the cartilage signal — and keeps it animal-only. [Animal] A review of peptides for chondrogenic induction and cartilage regeneration in osteoarthritis lists AOD-9604 among compounds with animal-model cartilage-regeneration evidence, citing the collagenase-induced rabbit knee-OA study as its sole primary source (Liao, Chen & Chang, Cartilage 2024; primary data from Kwon & Park, Ann Clin Lab Sci 2015). No human cartilage data are cited.

Claims that don't hold up

• "The main event of AOD-9604 is chondrogenesis — it rebuilds cartilage." The cartilage evidence is entirely animal and in vitro. The only peer-reviewed data come from a collagenase-induced rabbit osteoarthritis model, where intra-articular AOD-9604 (most effective combined with hyaluronic acid) was associated with cartilage regeneration (Kwon & Park, Ann Clin Lab Sci 2015). There is no human cartilage-regeneration data. Presenting chondrogenesis as an established human benefit overstates a preclinical signal. [Animal / In vitro]
• "There's a study in Growth Hormone & IGF Research showing AOD-9604 upregulates chondrocyte proliferation and collagen-II and aggrecan synthesis." This citation does not resolve: no such AOD-9604 paper appears in that journal or on PubMed. The in-vitro bovine-chondrocyte proteoglycan/collagen finding traces to a Metabolic Pharmaceuticals patent application (WO2013082667) cited inside the 2015 rabbit paper — unpublished company data, not a peer-reviewed study. Treat the specific journal citation as unverified. [In vitro / Hypothesis]
• "It fits almost exclusively the beta-3 receptor." An oversimplification. The same knockout data show beta3-independent actions (above), and the entire beta-3 story is mouse data, not confirmed in humans (Heffernan et al., Endocrinology 2001). [Animal]
• "Its risk profile is none — one of the safest bioactive compounds ever studied." The obesity program did report favorable tolerability with no measured effect on IGF-1, glucose or insulin (Moré & Kenley, J Endocrinol Metab 2014), but that reflects limited, short-term human exposure, not proof of zero risk. There is no long-term human safety surveillance, and research-grade material carries documented identity/purity risks (Vanhee et al., Drug Test Anal 2014). "No risk / safest ever" is not a supportable scientific claim. [Human]
• Knee-replacement industry statistics (e.g. "1 in 10 serious complications," "35% inappropriate," a "$22.5 billion market"). Whatever their individual accuracy, these describe joint-replacement surgery, not AOD-9604. They are rhetorical framing, not evidence that the peptide repairs joints in people.